| __timestamp | Bristol-Myers Squibb Company | Catalyst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 4473654 |
| Thursday, January 1, 2015 | 5001000000 | 8597010 |
| Friday, January 1, 2016 | 5002000000 | 7910260 |
| Sunday, January 1, 2017 | 4849000000 | 7304399 |
| Monday, January 1, 2018 | 4551000000 | 15875961 |
| Tuesday, January 1, 2019 | 4871000000 | 36881187 |
| Wednesday, January 1, 2020 | 7661000000 | 44233754 |
| Friday, January 1, 2021 | 7690000000 | 49628000 |
| Saturday, January 1, 2022 | 7814000000 | 58183000 |
| Sunday, January 1, 2023 | 7772000000 | 133710000 |
| Monday, January 1, 2024 | 8414000000 |
Data in motion
In the competitive landscape of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Bristol-Myers Squibb Company and Catalyst Pharmaceuticals, Inc. have showcased contrasting strategies in this domain.
Bristol-Myers Squibb, a giant in the industry, has consistently maintained high SG&A expenses, peaking at approximately $7.8 billion in 2022. This reflects their expansive operations and robust marketing strategies. However, their SG&A costs have grown by about 36% since 2014, indicating a potential area for optimization.
In contrast, Catalyst Pharmaceuticals, a smaller player, has demonstrated remarkable efficiency. Their SG&A expenses, though increasing, have remained under $134 million in 2023, a fraction of Bristol-Myers Squibb's costs. This suggests a leaner operational model, with a focus on cost-effectiveness.
As the pharmaceutical industry evolves, the ability to optimize SG&A costs will remain a key differentiator for success.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Who Optimizes SG&A Costs Better? Pfizer Inc. or Catalyst Pharmaceuticals, Inc.
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Comparing Innovation Spending: Bristol-Myers Squibb Company and Catalyst Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Catalyst Pharmaceuticals, Inc.
Insmed Incorporated or Catalyst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: BioMarin Pharmaceutical Inc. vs Catalyst Pharmaceuticals, Inc.
Exelixis, Inc. vs Catalyst Pharmaceuticals, Inc.: SG&A Expense Trends
Veracyte, Inc. and Catalyst Pharmaceuticals, Inc.: SG&A Spending Patterns Compared